Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder | 4 | 354 | April 4, 2023 | |
| Long-acting injectable for schizophrenia approved in the EU | 0 | 191 | April 4, 2024 | |
| EU approves Otsuka/Lundbeck's Abilify Maintena | 3 | 861 | May 8, 2014 | |
| Otsuka’s schizophrenia drug filing U-turn amongst latest CHMP announcements | 0 | 236 | May 27, 2023 | |
| NDA for Long-Acting Injectable for Schizophrenia and Bipolar I Accepted | 0 | 198 | September 13, 2022 |